Abstract Library

#4661 Comparison of preoperative chemotherapy and radio ligand therapy on prognosis after surgical resection for locally advanced or hepatic metastatic pancreatic neuroendocrine tumours

Introduction: The role of preoperative treatments in improving the rate of radical resection and survival of either locally advanced (LA) or hepatic metastatic (HM) pancreatic neuroendocrine tumours (panNETs) is unclear.

Conference:

Presenting Author:

Authors: Provinciali L, de Mestier L, Pontillo D, Guarneri G, Partelli S,

Keywords: adjuvant therapy, chemotherapy, event free survival, liver transplantation, RadioLigand Therapy,

#4637 Non-functional retroperitoneal paraganglioma in a young patient: A case report

Introduction: Paragangliomas are neuroendocrine tumours arising in the parasympathetic nervous system, outside the adrenal gland. Retroperitoneal location is extremely rare. Non-functional paragangliomas often represent a diagnostic challenge.

Conference:

Presenting Author:

Authors: Aris H, Saidi M, Lahfa I,

Keywords: retroperitoneal paraganglioma, surgery, monitoring,

#4440 Efficacy of octreotide in treating advanced gastrointestinal and pancreatic neuroendocrine tumours: A retrospective cohort study

Introduction: Treatment of advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) lacks high-level evidence and remains controversial.

Conference:

Presenting Author: Wang H

Authors: Wang H, Wang Y, Wang C, Wang G, Chi Y,

Keywords: adjuvant therapy, octreotide, gastroenteropancreatic neuroendocrine tumour,

#4413 Efficacy and safety of adjuvant peptide receptor radionuclide therapy after curative surgery of locoregional limited small intestine neuroendocrine neoplasia (APSIN) – A multi-centre, prospective, randomised, controlled, phase III study

Introduction: Our multi-centre, prospective, open-label, two-arm parallel group, randomised, controlled, phase III study will address the efficacy and safety of adjuvant peptide receptor radionuclide therapy after curative surgery of locoregional limited small intestine neuroendocrine neoplasia.

Conference:

Presenting Author: Eilsberger F

Authors: Eilsberger F, Luster M, Rau J, Avci H, Schade-Brittinger C,

Keywords: adjuvant therapy, neuroendocrine neoplasia, small intestine, peptide receptor radionuclide therapy, PRRT,

#4065 DAREON™-7: A Phase I, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive neuroendocrine carcinomas

Introduction: Neuroendocrine carcinomas (NEC) have limited treatment options. DLL3 is highly expressed on NEC and is a promising treatment target. In an ongoing Phase I trial (NCT04429087), BI 764532, a DLL3/CD3 IgG-like T-cell engager (TcE), was tolerable with promising activity in pretreated pts with DLL3-positive (+) tumours, including NEC.

Conference:

Presenting Author: Capdevila J

Authors: Capdevila J, Vandamme T, Niccoli P, Mishima S, Kato K,

Keywords: neuroendocrine carcinoma, delta-like ligand, T-cell engager, Phase I,